RT Journal Article
SR Electronic
T1 Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.22.21266690
DO 10.1101/2021.11.22.21266690
A1 Holubar, Marisa
A1 Subramanian, Aruna
A1 Purington, Natasha
A1 Hedlin, Haley
A1 Bunning, Bryan
A1 Walter, Katharine S.
A1 Bonilla, Hector
A1 Boumis, Athanasia
A1 Chen, Michael
A1 Clinton, Kimberly
A1 Dewhurst, Liisa
A1 Epstein, Carol
A1 Jagannathan, Prasanna
A1 Kaszynski, Richard H.
A1 Panu, Lori
A1 Parsonnet, Julie
A1 Ponder, Elizabeth L.
A1 Quintero, Orlando
A1 Sefton, Elizabeth
A1 Singh, Upinder
A1 Soberanis, Luke
A1 Truong, Henry
A1 Andrews, Jason R.
A1 Desai, Manisha
A1 Khosla, Chaitan
A1 Maldonado, Yvonne
YR 2021
UL http://medrxiv.org/content/early/2021/11/24/2021.11.22.21266690.abstract
AB Background Favipiravir is an oral, RNA-dependent RNA polymerase inhibitor with in vitro activity against SARS-CoV2. Despite limited data, favipiravir is administered to patients with COVID-19 in several countries.Methods We conducted a phase 2 double-blind randomized controlled outpatient trial of favipiravir in asymptomatic or mildly symptomatic adults with a positive SARS-CoV2 RT-PCR within 72 hours of enrollment. Participants were randomized 1:1 to receive placebo or favipiravir (1800 mg BID Day 1, 800mg BID Days 2-10). The primary outcome was SARS-CoV-2 shedding cessation in a modified intention-to-treat (mITT) cohort of participants with positive enrollment RT-PCRs. Using SARS-CoV-2 deep sequencing, we assessed favipiravir’s impact on mutagenesis.Results From July 8, 2020 - March 23, 2021, we randomized 149 participants with 116 included in the mITT cohort. The participants’ mean age was 43 years (SD 12.5) and 57 (49%) were women. We found no difference in time to shedding cessation by treatment arm overall (HR 0.76 favoring placebo, 95% confidence interval [CI] 0.48 – 1.20) or in sub-group analyses (age, sex, high-risk comorbidities, seropositivity or symptom duration at enrollment). We observed no difference in time to symptom resolution (initial: HR 0.84, 95% CI 0.54 – 1.29; sustained: HR 0.87, 95% CI 0.52 – 1.45). We detected no difference in accumulation of transition mutations in the viral genome during treatment.Conclusions Our data do not support favipiravir use at commonly used doses in outpatients with uncomplicated COVID-19. Further research is needed to ascertain if higher doses of favipiravir are effective and safe for patients with COVID-19.Trial registration number NCT04346628Summary In this phase 2 double-blind randomized controlled outpatient trial of favipiravir in asymptomatic or uncomplicated patients with COVID-19, we found no difference in time to shedding cessation or time to symptom resolution by treatment arm.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04346628Funding StatementThis study was funded by anonymous donors to Stanford University. The funders had no role in data collection, analysis, or the decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Stanford University School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.